国药新冠疫苗获准向内地3至17岁儿童及青少年接种
中国疾控中心研究员、科研攻关组疫苗研发专班专家组成员邵一鸣周五(11日)表示,经国家有关部门的批准,国药中生北京所和北京科兴中维公司的新冠疫苗,在有需要的情况下可用於3至17岁人群的疫苗接种。
邵氏称,国药中生北京所和北京科兴中维公司研制的灭活疫苗在获得附条件上市批准以後,继成人使用之後,继续开展了3至17岁人群的扩大临床试验,积累了更多的数据,这些数据及时上报国家,经过专家的认真审评论证,充分证明在3至17岁这个人群是安全的。
此前科兴新冠灭活疫苗在内地的紧急使用年龄从18岁以上扩大至3岁以上。据国家卫健委数据显示,截至6月10日,内地累计报告接种新冠病毒疫苗8.45亿剂次,当日增加2,044.3万剂次。
邵一鸣补充,内地新冠疫苗使用人群最先是在18岁以上的成人开始的,现在成人接种最大年龄超过100岁,累计已经接种了8亿多剂次,也是国际上单个国家接种剂次最多的。在这些大规模接种当中,大量数据证明了中国的新冠疫苗是安全和有效的。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.